Boldine: a potential new antiproliferative drug against glioma cell lines
- 359 Downloads
Malignant gliomas are the most common and devastating primary tumors of the central nervous system. Currently no efficient treatment is available. This study evaluated the effect and underlying mechanisms of boldine, an aporphine alkaloid of Peumus boldus, on glioma proliferation and cell death. Boldine decreased the cell number of U138-MG, U87-MG and C6 glioma lines at concentrations of 80, 250 and 500 μM. We observed that cell death caused by boldine was cell-type specific and dose-dependent. Exposure to boldine for 24 h did not activate key mediators of apoptosis. However, it induced alterations in the cell cycle suggesting a G2/M arrest in U138-MG cells. Boldine had no toxic effect on non-tumor cells when used at the same concentrations as those used on tumor cells. Based on these results, we speculate that boldine may be a promising compound for evaluation as an anti-cancer agent.
KeywordsGlioma Proliferation Boldine Anti-tumor agent
This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The authors thank Alessandra Heizelmann for the excellent technical assistance.
- 1.Aygeropoulos NG, Batchelor TT (1999) New treatment strategies for malignant gliomas. Oncologist 4:209–224Google Scholar
- 2.Davis FG, McCarthy BJ, Freels S (1999) The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85:85–491, doi: 10.1002/(SICI)1097-0142(19990101)85:1<85::AID-CNCR12>3.0.CO;2-A CrossRefGoogle Scholar
- 5.Trog D, Fountoulakis M, Friedlein A et al (2006) Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 6:2924–2930, doi: 10.1002/pmic.200500587 CrossRefPubMedGoogle Scholar